AMPH250117C40000
- 0.50
- -0.50-50.00%
Amphastar Pharmaceuticals Newsroom
Amphastar Pharma Analyst Ratings
Wells Fargo Initiates Amphastar Pharmaceuticals(AMPH.US) With Buy Rating, Announces Target Price $55
Piper Sandler Maintains Amphastar Pharmaceuticals(AMPH.US) With Buy Rating, Maintains Target Price $66
Needham Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating
Capital One Financial Maintains Amphastar Pharmaceuticals(AMPH.US) With Buy Rating, Maintains Target Price $70
Amphastar Pharmaceuticals: Strong Product Pipeline and Financial Position Justify Buy Rating
Organon Downgraded, Amneal Upgraded as J.P. Morgan Reviews Specialty Pharma
Capital One Financial Maintains Amphastar Pharmaceuticals(AMPH.US) With Buy Rating, Maintains Target Price $70
Amphastar Pharmaceuticals Poised for Growth: Strong Product Performance and Strategic Financial Health Drive Buy Rating
Amphastar Pharmaceuticals (AMPH) Gets a Buy From Piper Sandler
Amphastar Pharma Analyst Ratings
Amphastar Pharmaceuticals Hold Rating Affirmed Amid Competitive Pressures and Pipeline Challenges
Analysts Offer Insights on Healthcare Companies: Amphastar Pharmaceuticals (AMPH), Revolution Medicines (RVMD) and Personalis (PSNL)
Needham Sticks to Their Hold Rating for Amphastar Pharmaceuticals (AMPH)
Amphastar Pharmaceuticals Upholds Buy Rating Amid Strong Q2 Earnings and Promising Growth Outlook
Capital One Financial Maintains Amphastar Pharmaceuticals(AMPH.US) With Buy Rating, Maintains Target Price $70
Analysts' Top Healthcare Picks: Align Tech (ALGN), Amphastar Pharmaceuticals (AMPH)
Bank of America Securities Reaffirms Their Hold Rating on Amphastar Pharmaceuticals (AMPH)
Amphastar Pharma Analyst Ratings
Piper Sandler Reiterates Overweight on Amphastar Pharma, Maintains $71 Price Target